Systemic administration of MPTP induces thalamic neuronal degeneration in mice

Brain Research

Volumn 759, Issue 1, 1997, Pages 9-17

  Freyaldenhoven, Tim E ^a,b   Ali, Syed F ^a,b   Schmued, Larry C ^a  

^a National Centre   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Fluoro Jade; Mice; MPTP; Neuronal degeneration; Parkinson's disease; Substantia nigra; Thalamus

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CATECHOLAMINE; HEAT SHOCK PROTEIN; NEUROTOXIN; NOMIFENSINE; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CATECHOLAMINE NERVE CELL; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NERVE CELL DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; THALAMUS; THALAMUS NUCLEUS; VENTRAL TEGMENTUM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DIZOCILPINE MALEATE; DOPAMINE AGENTS; MALE; MICE; MICE, INBRED STRAINS; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; NOMIFENSINE; SELEGILINE; SUBSTANTIA NIGRA; TEMPERATURE; THALAMUS;

EID: 0030833669     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00045-0     Document Type: Article

References (62)

1. Adams J.D. Jr., Klaidman L.K., Leung A.C. MPP+ and MPDP induced oxygen radical formation with mitochondrial enzymes. Free Rad. Biol. Med. 15:1993;181-186.
2. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
3. Ali S.F., David S.N., Newport G.D. Age-related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology. 14:1993;29-34.
4. Ali S.F., David S.N., Newport G.D., Cadet J.L., Slikker W. Jr. MPTP-induced oxidative stress and neurotoxicity are age-dependent: Evidence from measures of reactive oxygen species and striatal dopamine levels. Synapses. 18:1994;27-34.
5. Bentivoglio M., Balercia G., Kruger L. The specificty of the nonspecific thalamus: The midline nuclei. Prog. Brain Res. 87:1991;53-80.
6. Bergman M., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesion of the subthalamic nucleus. Science. 249:1990;1436-1438.
7. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in pars compacta of the substantia nigra by 1-methyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA. 80:1983;4546-4550.
8. Candy J.M., Perry R.H., Perry E.K., Irving D., Blessed G., Fairbairn A.F., Tomlinson B.E. Pathological changes in the nucleus basalis of Meynert in Alzheimer's and Parkinson's disease. J. Neurol. Sci. 54:1983;277-289.
9. Chan P., Langston J.W., Di Monte D.A. MK-801 temporarily prevents MPTP-induced acute dopamine depletion and MPP+ elimination in the mouse striatum. J. Pharmacol. Exp. Ther. 267:1993;1515-1520.
10. Chiueh C.C., Burns R.S., Markey S.P., Jacobowitz D.M., Kopin I.J. Primate model of parkinonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in the rhesus monkey. Life Sci. 80:1985;213-218.
11. Chiueh C.C., Miyake H., Peng M. Role of dopamine autooxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 60:1993;251-258.
12. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reihert C.M., Kopin I.J. Chronic parkinsonism secondary to intravenous injection of meperidine analogs. Psychiatr. Res. 1:1979;249-254.
13. de Olmos J.S., Beltramino C.A., de Olmos De Lorenzo S. Use of an amino-cupric-silver technique for the detection of early and semiacute neuronal degeneration caused by neurotoxicants, hypoxia, and physical trauma. Neurotoxicol. Teratol. 16:1994;545-561.
14. +-induced neurotoxicity in mouse is age-dependent: Evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715:1996;1-8.
15. B. Dubois, B. Pillon, Biochemical correlates of cognitive changes and dementia in Parkinson's disease, in: S.J. Huber, J.L. Cummings (Eds.), Parkinson's Disease, Neurobehavioral Aspects, Oxford University Press, New York, 1992, pp. 178-198.
16. Forno L.S., DeLanney L.E., Irwin I., Langston J.W., Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20:1986;449-455.
17. Freyaldenhoven T.E., Ali S.F. MPTP- and MPP+-induced effects on body temperature exhibit age- and strain-dependence in mice. Brain Res. 688:1995;161-170.
18. +. Brain Res. 735:1996;42-49.
19. 3H-DOPA in various regions of the brain. J. Neurochem. 13:1966;655-669.
20. Goto S., Hirano A. Catecholaminergic neurons in the parabrachial nuclues of normal individuals and patients with idiopathic parkinson's disease. Ann. Neurol. 30:1991;192-196.
21. Groenewegen H.J., Berendse H.W. The specificity of the 'nonspecific' midline and intralaminar thalamic nuclei. Trends Neurosci. 17:1994;52-57.
22. Groenewegen H.J., Berendse H.W., Wolters J.G., Lohman A.H.M. The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus and the amygdala: Evidence for a parallel organization. Prog. Brain. Res. 85:1990;95-118.
23. Grunwerg B.S., Krauthamer G.M. Sensory responses of intralaminar thalamic neurons activated by the superior colliculus. Exp. Brain Res. 88:1992;541-550.
24. Hallman H., Lange J., Olson L., Stromberg I., Jonsson G Neurochemical and histochemical characterization of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse. J. Neurochem. 44:1985;117-127.
25. Heikkila R.E., Hess A., Duvoisin R.D. Dopaminergic neurotoxicity of 1-methyl-1,2,3,6-tetrahydropyridine in mice. Science. 224:1984;1451-1453.
26. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 311:1984;467-469.
27. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 334:1988;345-348.
28. Hokfelt T., Johansson O., Fuxe K., Goldstein M., Park D. Immunohistochemical studies on the localization and distribution of monoamine neuron systems in the rat brain. I. Tyrosine hydroxylase in the mes and diencephalon. Med. Biol. 54:1976;427-453.
29. Jankovic J., McDermott M., Carter J.et al. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. Neurology. 40:1990;1529-1534.
30. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177.
31. Javitch J.A., Uhl G.R., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterization and localization of receptor binding sites in rat and human brain. Proc. Natl. Acad. Sci. USA. 81:1984;4591-4595.
32. Jones M.W., Kilpatrick I.C., Phillipson O.T. Regulation of dopamine function in the nucleus accumbens of the rat by the thalamic paraventricular nucleus and adjacent midline nuclei. Exp. Brain Res. 76:1989;572-580.
33. Jonsson G., Sundstrom E., Mefford I., Olson L., Johnson S., Freedman R., Hoffer B. Electrophysiologocal and neurochemical correlates of the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in the mouse. Naunyn Schmiedebergs Arch. Pharmacol. 331:1985;1-6.
34. Kilpatrick I.C., Jones M.W., Johnson B.J., Cornwall J., Phillipson O.T. Thalamic control of dopaminergic functions in the caudate-putamen of the rat. II. Studies using ibotenic acid injection of the parafascicular-intralaminar nuclei. Neuroscience. 19:1986;979-990.
35. Kilpatrick I.C., Phillipson O.T. Thalamic control of dopaminergic function in the caudate-putamen of the rat. I. The influence of electrical stimulation of the parafascicular nucleus on dopamine utilization. Neuroscience. 19:1986;965-978.
36. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
37. Langston J.W., Irwin I., Langston E.B., Forno L.S. Pargyline prevents MPTP-induced parkinsonism in primates. Science. 225:1984;1480-1482.
38. G. Macchi and M. Bentivoglio, The thalamic intralaminar nuclei and the cerebral cortex, in: Sensory-Motor Areas and Aspects of Cortical Connectivity Cerebral Cortex, Vol. 5, Plenum Press, New York, 1986, pp. 355-401.
39. Mayeux R., Stern Y., Rosen J., Leventhal J. Depression, intellectual impairment, and Parkinson's disease. Neurology. 31:1981;645-650.
40. Miller D.B., O'Callaghan J.P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270:1994;752-760.
41. Mitchell I.J., Cross A.J., Sambrook M.A., Crossman A.R. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neurosci. Lett. 61:1985;195-200.
42. Moga M.M., Weis R.P., Moore R.Y. Efferent projections of the paraventricular thalamic nucleus in the rat. J. Comp. Neurol. 359:1995;221-238.
43. Naoi M., Takahashi T., Nagatsu T. A fluorometric determination of N-methyl-4-phenylpyridinium ion, using high-performance liquid chromatography. Anal. Biochem. 162:1987;540-545.
44. Niklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sci. 36:1985;2503-2508.
45. Rajput A.H., Rozdilsky B. Dysautonomia in parkinsonism: A clinicopathological study. J. Neurol. Neurosurg. Psychiatry. 39:1976;1092-1100.
46. Ramsay R.R., Singer T.P. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J. Biol. Chem. 261:1986;7585-7587.
47. Redmond D.E. Jr., Sladek J.R. Jr., Roth R.H., Collier T.J., Elsworth J.D., Deutch A.Y., Haber S. Fetal neuronal grafts in monkeys given methyl-phenyl-tetrahydropyridine. Lancet. 8490:1986;1125-1127.
48. Ricaurte G.A., Langston J.W., DeLanney L.W., Irwin I., Brooks J.D. Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) in the mouse striatum. Neurosci. Lett. 59:1985;259-264.
49. Satoh K., Yomezawa A., Tadano T., Kisara K., Arai Y., Kinemuchi H. Acute effects of a parkinsonism-inducing neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on mouse body temperature. Life Sci. 41:1987;1415-1424.
50. L.C. Schmued, C. Albertson, W. Slikker Jr., Fluoro-Jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration, Brain Res., 752 (1997) 37-46.
51. Schneider J.S., Kovelowski C.J. II Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. 519:1990;122-128.
52. Schneider J.S. Chronic exposure to low doses of MPTP. II. Neuorchemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res. 534:1990;25-36.
53. Schneider J.S., Roeltgen D.P. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys. Brain Res. 615:1993;351-354.
54. Seniuk N.A., Tatton W.G., Greenwood C.E. Jr. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527:1990;7-20.
55. Srivastava R., Brouillet E., Flint Beal M., Storey E., Hyman B.T. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss. Neurobiol. Aging. 14:1993;295-301.
56. Stern Y., Tetrud J.W., Martin W.R.W., Kutner S.J., Langston J.W. Cognitive changes following MPTP exposure. Neurology. 40:1990;261-264.
57. L.A. Sternberger, Immunocytochemistry, 2nd ed., Wiley, New York, 1982, pp. 129-171.
58. Tabatabaei A., Perry T.L., Hansen S., Krieger C. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci. Lett. 141:1992;192-194.
59. Tetrud J.W., Langston J.W., Garbe P.L., Ruttenber A.J. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology. 39:1989;1483-1487.
60. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature. 349:1991;414-418.
61. Wichmann T., DeLong M.R. Pathophysiology of parkinsonian motor abnormalities. Adv. Neurol. 60:1993;53-61.
62. Xuereb J.H., Perry R.H., Candy J.M., Perry E.K., Marshall E., Bonham J.R. Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. Brain. 114:1991;363-1379.